DOP2016000061A - Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso - Google Patents

Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso

Info

Publication number
DOP2016000061A
DOP2016000061A DO2016000061A DO2016000061A DOP2016000061A DO P2016000061 A DOP2016000061 A DO P2016000061A DO 2016000061 A DO2016000061 A DO 2016000061A DO 2016000061 A DO2016000061 A DO 2016000061A DO P2016000061 A DOP2016000061 A DO P2016000061A
Authority
DO
Dominican Republic
Prior art keywords
methods
elaboration
polymeric nanoparticles
therapeutic polymeric
therapeutic
Prior art date
Application number
DO2016000061A
Other languages
English (en)
Inventor
Greg Troiano
Hong Wang
Marianne Bernice Ashford
James Martin Nolan Iii
Eyoung Shin
Young-Ho Song
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51619214&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DOP2016000061(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of DOP2016000061A publication Critical patent/DOP2016000061A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Manufacturing & Machinery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBEN AQUÍ NANOPARTÍCULAS POLIMÉRICAS QUE INCLUYEN UN AGENTE TERAPÉUTICO QUE ES 2-(3-((7-(3-(ETIL(2-HIDROXIETIL)AMINO)PROPOXI)QUINAZOLIN-4-IL)AMINO)-1H-PIRAZOL-5-IL)-N-(3-FLUOROFENIL)ACETAMIDA (TAMBIÉN CONOCIDO COMO AZD1152 HQPA) O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE ESTE, Y LOS MÉTODOS DE FABRICACIÓN Y USO DE TALES NANOPARTÍCULAS TERAPÉUTICAS.
DO2016000061A 2013-09-16 2016-03-10 Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso DOP2016000061A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361878227P 2013-09-16 2013-09-16
US201461939332P 2014-02-13 2014-02-13

Publications (1)

Publication Number Publication Date
DOP2016000061A true DOP2016000061A (es) 2016-03-31

Family

ID=51619214

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000061A DOP2016000061A (es) 2013-09-16 2016-03-10 Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso

Country Status (38)

Country Link
US (2) US10047072B2 (es)
EP (2) EP3311845B1 (es)
JP (1) JP6543258B2 (es)
KR (1) KR102307175B1 (es)
CN (1) CN105555315B (es)
AP (1) AP2016009088A0 (es)
AU (2) AU2014320088B2 (es)
BR (1) BR112016004922B1 (es)
CA (1) CA2922279C (es)
CL (1) CL2016000556A1 (es)
CR (1) CR20160130A (es)
CY (1) CY1119398T1 (es)
DK (2) DK3046584T3 (es)
DO (1) DOP2016000061A (es)
ES (2) ES2640648T3 (es)
GT (1) GT201600050A (es)
HR (2) HRP20171365T1 (es)
HU (2) HUE034490T2 (es)
IL (2) IL244174B (es)
LT (2) LT3046584T (es)
ME (1) ME02860B (es)
MX (1) MX370490B (es)
MY (1) MY191804A (es)
NI (1) NI201600037A (es)
PE (1) PE20160930A1 (es)
PH (1) PH12016500499A1 (es)
PL (2) PL3311845T3 (es)
PT (2) PT3311845T (es)
RS (2) RS56362B1 (es)
RU (1) RU2682332C2 (es)
SG (1) SG11201601218PA (es)
SI (2) SI3311845T1 (es)
SM (2) SMT201700442T1 (es)
TN (1) TN2016000077A1 (es)
TW (1) TWI644674B (es)
UY (1) UY35738A (es)
WO (1) WO2015036792A1 (es)
ZA (2) ZA201602201B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
DK3104838T3 (da) * 2014-02-13 2020-02-24 Pfizer Terapeutiske nanopartikler omfattende et terapeutisk middel og fremgangsmåder til fremstilling og anvendelse deraf
WO2017081606A1 (en) * 2015-11-10 2017-05-18 Pfizer Inc. Methods of determining features of polymeric nanoparticles that include a therapeutic agent
WO2017089942A1 (en) * 2015-11-25 2017-06-01 Pfizer Inc. Therapeutic nanoparticles comprising an antibiotic and methods of making and using same
JP6579948B2 (ja) * 2015-12-24 2019-09-25 株式会社日立ハイテクノロジーズ 生体ポリマを分析するための測定試薬及び分析デバイス
EP3432864B1 (en) * 2016-03-22 2020-05-06 Pfizer Inc Process for preparing therapeutic nanoparticles
WO2018181542A1 (ja) * 2017-03-29 2018-10-04 テルモ株式会社 アジュバント組成物およびこれを含むワクチン組成物並びに薬剤キット
TW202019440A (zh) 2018-07-30 2020-06-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
TW202023568A (zh) * 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
US20210369631A1 (en) * 2019-02-02 2021-12-02 Nanobrid Innovations Private Limited A lipid-polymer hybrid nanoparticle
US11123734B2 (en) 2019-07-31 2021-09-21 CytoVale Inc. System and method for immune activity determination
WO2021037933A1 (en) 2019-08-28 2021-03-04 Astrazeneca Ab Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
WO2021224381A1 (en) 2020-05-07 2021-11-11 Astrazeneca Ab Combination therapy for treating cancer
WO2021260582A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and aurora b inhibitor
WO2022192139A1 (en) 2021-03-10 2022-09-15 Astrazeneca Ab Aurora kinase b inhibitors for use for treating cancer
MX2024001681A (es) * 2021-08-05 2024-03-04 Medincell S A Composicion farmaceutica.
US11548003B1 (en) * 2022-01-13 2023-01-10 CytoVale Inc. System and method for determining an immune activation state
US11592371B1 (en) 2022-01-13 2023-02-28 CytoVale Inc. System and method for determining an immune activation state
US11964281B2 (en) 2022-02-03 2024-04-23 CytoVale Inc. System and method for correcting patient index
US20250064971A1 (en) * 2022-02-04 2025-02-27 Virginia Commonwealth University Sustained release formulations and methods of use thereof

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
GB9017479D0 (en) 1990-08-09 1990-09-26 Ici Plc Process
GB9102727D0 (en) 1991-02-08 1991-03-27 Ici Plc Pharmaceutical agent
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5565215A (en) 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (es) 1994-11-12 1997-12-01 Zeneca Ltd
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
DK0752245T3 (da) 1995-07-05 2002-09-09 Europ Economic Community Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ES2241324T3 (es) 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
FI982733L (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
EE200200119A (et) 1999-09-21 2003-04-15 Astrazeneca Ab Kinasoliini derivaadid ja nende kasutamine ravimitena
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
BR0111754A (pt) 2000-06-28 2003-04-29 Astrazeneca Ab Uso de um composto, método para inibir aurora 2 quinase em um animal de sangue quente, composto, e, composição farmacêutica
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
WO2002078674A1 (en) 2001-03-30 2002-10-10 Trustees Of Princeton University A process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
JP2005508939A (ja) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
ATE446093T1 (de) 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
DE60326597D1 (de) 2002-06-05 2009-04-23 Univ Florida Ophthalmisches arzneimittelabgabesystem
EP2283864A1 (en) 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
CN1684663A (zh) 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
UA83814C2 (ru) * 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
JP4927535B2 (ja) 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
AU2004259209A1 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
US9028829B2 (en) 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
ES2246694B1 (es) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. Nanoparticulas pegiladas.
US8945629B2 (en) 2004-09-10 2015-02-03 University Of Wyoming Nanoparticles for cytoplasmic drug delivery to cancer cells
JP2008535924A (ja) 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
US20090022806A1 (en) 2006-12-22 2009-01-22 Mousa Shaker A Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2010009146A1 (en) 2008-07-15 2010-01-21 University Of Kansas Nanoclusters for delivery of poorly water soluble drug nanoparticles
EP1985309B1 (en) 2005-12-26 2016-11-23 LTT Bio-Pharma Co., Ltd. Nanoparticles containing water-soluble non-peptide low-molecular weight drug
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
GB0609621D0 (en) * 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
GB0609617D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Process & intermediate
WO2007137117A2 (en) 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
WO2008016016A1 (fr) 2006-07-31 2008-02-07 Senju Pharmaceutical Co., Ltd. Préparation liquide aqueuse contenant un amide
US20100144845A1 (en) 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
US20100015050A1 (en) 2006-12-21 2010-01-21 Wayne State University Peg and targeting ligands on nanoparticle surface
EP3417859A1 (en) 2007-03-07 2018-12-26 Abraxis BioScience, LLC Nanoparticle comprising rapamycin and albumin as anticancer agent
US20090074828A1 (en) 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
AU2008240155B2 (en) 2007-04-13 2012-09-20 University Of North Texas Health Science Center At Fort Worth Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics
WO2008139804A1 (ja) 2007-05-14 2008-11-20 Ltt Bio-Pharma Co., Ltd. 徐放性の陰荷電基を持つ低分子薬物含有ナノ粒子
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US8974814B2 (en) 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
US9422234B2 (en) 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
WO2009073193A2 (en) 2007-12-03 2009-06-11 The Johns Hopkins University Methods of synthesis and use of chemospheres
KR100961880B1 (ko) 2007-12-12 2010-06-09 중앙대학교 산학협력단 밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
US20110182946A1 (en) 2008-03-17 2011-07-28 Board Of Regents, The University Of Texas System Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques
CA2721153C (en) * 2008-04-10 2018-10-02 Abraxis Bioscience, Llc Compositions of hydrophobic taxane derivatives and uses thereof
US20090312402A1 (en) 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
JP2011525180A (ja) 2008-06-16 2011-09-15 バインド バイオサイエンシズ インコーポレイテッド 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
AU2009268923B2 (en) 2008-06-16 2015-09-17 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EA020753B1 (ru) 2008-06-16 2015-01-30 Бинд Терапьютикс, Инк. Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение
CN102099016A (zh) * 2008-06-16 2011-06-15 佰恩德生物科学股份有限公司 载药的聚合物纳米微粒及其制备和使用方法
WO2010030763A2 (en) 2008-09-10 2010-03-18 Bind Biosciences, Inc. High throughput fabrication of nanoparticles
WO2010042555A2 (en) 2008-10-06 2010-04-15 The Brigham And Women's Hospital, Inc. Particles with multiple functionalized surface domains
US20110125090A1 (en) 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
EA201100765A1 (ru) 2008-12-15 2012-04-30 Бинд Биосаиэнсис Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств
JP5616905B2 (ja) * 2009-01-31 2014-10-29 アッヴィ・インコーポレイテッド オーロラキナーゼｂ阻害剤治療に対する応答性を予見およびモニターするためのマーカー
WO2010091187A2 (en) 2009-02-04 2010-08-12 The Brigham And Women's Hospital, Inc. Polymeric nanoparticles with enhanced drug-loading and methods of use thereof
US20120177741A1 (en) * 2009-09-29 2012-07-12 Eyegate Pharmaceuticals, Inc. Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP2512459A4 (en) 2009-12-15 2013-08-07 THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING EPOTHILONE AND METHODS OF MAKING AND USING SAME
EP2512487A4 (en) 2009-12-15 2013-08-07 THERAPEUTIC POLYMERNANOPARTICLES WITH CORTICOSTEROIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF
JP5965844B2 (ja) * 2009-12-15 2016-08-10 バインド セラピューティックス インコーポレイテッド 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
US8207290B2 (en) 2010-03-26 2012-06-26 Cerulean Pharma Inc. Methods and systems for generating nanoparticles
CN107029223A (zh) 2010-05-26 2017-08-11 西莱克塔生物科技公司 合成纳米载体联合疫苗
KR20130100290A (ko) 2010-08-30 2013-09-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 협착성 병변을 위한 전단 제어 방출 및 혈전 용해 치료법
WO2012039979A2 (en) 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
ES2386177B1 (es) 2010-09-21 2013-09-23 Lipotec, S.A. Nanocapsulas conteniendo microemulsiones
WO2012040513A1 (en) 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Compositions and methods for the delivery of beta lapachone
WO2012051426A2 (en) 2010-10-15 2012-04-19 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
EA201390600A1 (ru) 2010-10-22 2013-09-30 Байнд Терапьютикс, Инк. Терапевтические наночастицы с сополимерами с большим молекулярным весом
KR101304597B1 (ko) 2010-11-02 2013-09-12 한남대학교 산학협력단 멀티-코어 구조를 갖는 생체적합성 입자의 제조방법 및 이에 의해 제조된 멀티-코어 구조를 갖는 생체적합성 입자
FR2967581B1 (fr) 2010-11-19 2012-12-28 Sanofi Aventis Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques
JP6112615B2 (ja) 2011-01-24 2017-04-12 イッサム リサーチ ディべロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム，リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ，Ｌｔｄ． 薬物の皮膚及び全身送達のためのナノ粒子
US20140035438A1 (en) 2011-04-12 2014-02-06 Massachusetts Institute Of Technology Passive, Self-Tuning Energy Harvester for Extracting Energy From Rotational Motion
WO2013044219A1 (en) 2011-09-22 2013-03-28 Bind Biosciences Methods of treating cancers with therapeutic nanoparticles
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
ES2685743T3 (es) 2012-02-29 2018-10-11 Merck Patent Gmbh Procedimiento para la fabricación de nanopartículas cargadas con principio activo
CA2867203C (en) 2012-03-16 2016-09-20 The Johns Hopkins University Non-linear multiblock copolymer-drug conjugates for the delivery of active agents
HUE043998T2 (hu) 2012-09-17 2019-09-30 Pfizer Eljárás terápiás nanorészecskék elõállítására
BR112015005878A2 (pt) * 2012-09-17 2017-07-04 Bind Therapeutics Inc nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
JP2016519091A (ja) * 2013-03-18 2016-06-30 ジェノシアンス ファルマ 新規抗がん剤としてのキノリン誘導体

Also Published As

Publication number Publication date
SI3311845T1 (sl) 2020-06-30
TWI644674B (zh) 2018-12-21
TW201605458A (zh) 2016-02-16
KR102307175B1 (ko) 2021-10-01
RU2016110351A (ru) 2017-10-23
MX2016003437A (es) 2016-06-21
KR20160054590A (ko) 2016-05-16
AU2014320088B2 (en) 2017-06-01
US20150140104A1 (en) 2015-05-21
ME02860B (me) 2018-04-20
CR20160130A (es) 2016-06-20
HUE048498T2 (hu) 2020-07-28
CL2016000556A1 (es) 2016-09-09
US10047072B2 (en) 2018-08-14
PL3311845T3 (pl) 2020-06-15
UY35738A (es) 2015-03-27
SMT202000162T1 (it) 2020-05-08
DK3046584T3 (en) 2017-10-02
HK1254347A1 (en) 2019-07-19
MY191804A (en) 2022-07-15
RU2682332C2 (ru) 2019-03-19
CY1119398T1 (el) 2018-03-07
HRP20171365T1 (hr) 2017-11-03
US20190092757A1 (en) 2019-03-28
ES2784423T3 (es) 2020-09-25
SG11201601218PA (en) 2016-04-28
CA2922279C (en) 2022-08-16
EP3046584B1 (en) 2017-07-19
NZ717615A (en) 2021-08-27
PT3046584T (pt) 2017-09-18
RS56362B1 (sr) 2017-12-29
PH12016500499B1 (en) 2016-06-13
AU2014320088A1 (en) 2016-03-10
ES2640648T3 (es) 2017-11-03
EP3311845A1 (en) 2018-04-25
AP2016009088A0 (en) 2016-03-31
AU2017208307B2 (en) 2018-08-09
IL279767A (en) 2021-01-31
PL3046584T3 (pl) 2017-11-30
SMT201700442T1 (it) 2017-11-15
PH12016500499A1 (en) 2016-06-13
AU2017208307A1 (en) 2017-08-17
ZA201602201B (en) 2022-05-25
US10577351B2 (en) 2020-03-03
LT3046584T (lt) 2017-10-10
TN2016000077A1 (en) 2017-07-05
IL244174B (en) 2021-01-31
WO2015036792A1 (en) 2015-03-19
ZA201706497B (en) 2019-02-27
HRP20200407T1 (hr) 2020-06-12
CN105555315B (zh) 2019-05-07
CA2922279A1 (en) 2015-03-19
BR112016004922A2 (es) 2017-08-01
JP6543258B2 (ja) 2019-07-10
EP3046584A1 (en) 2016-07-27
IL279767B (en) 2021-09-30
RU2016110351A3 (es) 2018-06-28
RS60093B1 (sr) 2020-05-29
BR112016004922B1 (pt) 2022-08-23
IL244174A0 (en) 2016-04-21
DK3311845T3 (da) 2020-04-06
EP3311845B1 (en) 2020-01-15
GT201600050A (es) 2019-08-12
CN105555315A (zh) 2016-05-04
SI3046584T1 (sl) 2017-10-30
HUE034490T2 (en) 2018-02-28
JP2016530324A (ja) 2016-09-29
MX370490B (es) 2019-12-16
NI201600037A (es) 2016-09-21
LT3311845T (lt) 2020-04-10
PE20160930A1 (es) 2016-09-03
PT3311845T (pt) 2020-04-02

Similar Documents

Publication Publication Date Title
NI201600037A (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
DOP2016000244A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y formas para su elaboración y uso
CL2017001061A1 (es) Cromanos sustituidos y métodos para su uso
NI201500036A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y métodos para realizarlas y usarlas.
CL2018000455A1 (es) Miembro de la banda para el uso de máscara de respiración y cuna para la cabeza que incluye el mismo
MX2015012933A (es) Micrordenamiento para suministro de agente terapeutico y metodos de uso.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CR20140365A (es) Compuestos de carbamato y preparación y uso de los mismos
BR112016009071A8 (pt) Composição cosmética em forma de nanofibras, método de produção de composição e uso
EA201790785A1 (ru) Производные тетрагидроизохинолина
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
MX2016001480A (es) Formulacion de inhibidores de syk.
CL2015002897A1 (es) Inhibidores de bace1
ECSP17081322A (es) Moduladores alostéricos positivos del receptor muscarínico m2
ECSP17059323A (es) Formulacion de combinacion de tesofensina y betabloqueante
CL2015001085A1 (es) Formulacion de liberación prolongada que comprende oprozomib y ademas uno o mas polimeros farmaceuticamente aceptables; metodo de preparacion de la formulacion; metodo para tratar cancer.
PL3288588T3 (pl) Ulepszone środki sieciujące włókna kolagenowe do stosowania w leczeniu ektazji rogówki
ES2666382T8 (es) Ortesis activa para la rehabilitación neurológica del movimiento de los miembros inferiores, sistema que comprende dicha órtesis y proceso para poner en funcionamiento dicho sistema
MX2016014859A (es) Composiciones farmaceuticas que comprenden danirixina para tratar enfermedades infecciosas.
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
BR112018012949A2 (pt) reguladores cftr e métodos de uso dos mesmos
IL258172A (en) Adaptation, process and use for introducing ingredients into the bladder via voiding without a catheter
MX390899B (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
CL2017001390A1 (es) Camkk1 como un nuevo regenerativo terapéutico